The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

(Image Credits: Pixabay) Fatty liver disease, medically known as hepatic steatosis ... stage involves significant inflammation and liver damage. NASH can lead to fibrosis and, eventually ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

The AIM-NASH tool is expected to enhance the reliability and efficiency of clinical trials for new MASH treatments by reducing variability in measuring disease activity (inflammation and fibrosis).

GLP-1 receptor agonists, such as semaglutide, show promise in resolving NASH and improving fibrosis without worsening the condition. Dual and triple agonists targeting multiple metabolic pathways ...

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

Details of the poste Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory ... Idiopathic Pulmonary Fibrosis (“IPF”) Company ...

AH is histologically characterised by cellular processes, including steatosis, inflammation and cell death ... Alcohol-associated hepatitis (AH) is histologically characterised by inflammation, ...

This manuscript presents a detailed characterization of male and female wildtype and Ctrp10 knockout mice, and reveals that knockout mice develop female-specific obesity that is largely uncoupled from ...